NO981578L - FremgangsmÕte for hemming av plasminogenaktivatorhemmer I - Google Patents
FremgangsmÕte for hemming av plasminogenaktivatorhemmer IInfo
- Publication number
- NO981578L NO981578L NO981578A NO981578A NO981578L NO 981578 L NO981578 L NO 981578L NO 981578 A NO981578 A NO 981578A NO 981578 A NO981578 A NO 981578A NO 981578 L NO981578 L NO 981578L
- Authority
- NO
- Norway
- Prior art keywords
- plasminogen activator
- activator inhibitor
- inhibiting plasminogen
- inhibiting
- hexamethylenimine
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 title 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 title 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 abstract 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 abstract 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US501595P | 1995-10-10 | 1995-10-10 | |
| PCT/US1996/016059 WO1997013511A1 (en) | 1995-10-10 | 1996-10-07 | Methods of inhibiting plasminogen activator inhibitor 1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO981578D0 NO981578D0 (no) | 1998-04-07 |
| NO981578L true NO981578L (no) | 1998-04-07 |
Family
ID=21713702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO981578A NO981578L (no) | 1995-10-10 | 1998-04-07 | FremgangsmÕte for hemming av plasminogenaktivatorhemmer I |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5731328A (cs) |
| EP (1) | EP0854715B1 (cs) |
| JP (1) | JPH11513665A (cs) |
| KR (1) | KR19990064099A (cs) |
| CN (1) | CN1199337A (cs) |
| AR (1) | AR003812A1 (cs) |
| AT (1) | ATE255414T1 (cs) |
| AU (1) | AU716655B2 (cs) |
| CA (1) | CA2234404A1 (cs) |
| CO (1) | CO4750819A1 (cs) |
| CZ (1) | CZ106098A3 (cs) |
| DE (1) | DE69630969T2 (cs) |
| EA (1) | EA001003B1 (cs) |
| ES (1) | ES2211981T3 (cs) |
| HU (1) | HUP9802348A3 (cs) |
| NO (1) | NO981578L (cs) |
| NZ (1) | NZ319948A (cs) |
| PL (1) | PL326294A1 (cs) |
| WO (1) | WO1997013511A1 (cs) |
| ZA (1) | ZA968444B (cs) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2207141A1 (en) * | 1996-07-15 | 1998-01-15 | David Thompson Berg | Benzothiophene compounds, and uses and formulations thereof |
| US5792798A (en) * | 1996-07-29 | 1998-08-11 | Eli Lilly And Company | Method for inhibiting plasminogen activator inhibitor 1 |
| US6025373A (en) * | 1997-04-22 | 2000-02-15 | Eli Lilly And Company | Methods for reducing fibrinogen |
| EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| WO2001074793A2 (en) | 2000-04-03 | 2001-10-11 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
| WO2006088011A1 (ja) * | 2005-02-15 | 2006-08-24 | Tokai University Educational System | プラスミノーゲンアクチベーターインヒビター－１阻害剤 |
| WO2007047205A2 (en) * | 2005-10-11 | 2007-04-26 | Amano Enzyme Usa Co., Ltd. | Enzyme inhibitors of pai-1 |
| CN101544138B (zh) * | 2008-03-26 | 2012-05-23 | 山东新北洋信息技术股份有限公司 | 热转印打印机碳带回收装置 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| RU2127592C1 (ru) * | 1993-12-21 | 1999-03-20 | Эли Лилли Энд Компани | Средство для ингибирования окисления липидов низкой плотности и подавления атеросклероза |
-
1996
- 1996-09-04 US US08/708,868 patent/US5731328A/en not_active Expired - Fee Related
- 1996-10-07 WO PCT/US1996/016059 patent/WO1997013511A1/en not_active Application Discontinuation
- 1996-10-07 ZA ZA9608444A patent/ZA968444B/xx unknown
- 1996-10-07 JP JP9515120A patent/JPH11513665A/ja active Pending
- 1996-10-07 EP EP96934096A patent/EP0854715B1/en not_active Expired - Lifetime
- 1996-10-07 AT AT96934096T patent/ATE255414T1/de not_active IP Right Cessation
- 1996-10-07 PL PL96326294A patent/PL326294A1/xx unknown
- 1996-10-07 CN CN96197511A patent/CN1199337A/zh active Pending
- 1996-10-07 AU AU72596/96A patent/AU716655B2/en not_active Ceased
- 1996-10-07 CA CA002234404A patent/CA2234404A1/en not_active Abandoned
- 1996-10-07 ES ES96934096T patent/ES2211981T3/es not_active Expired - Lifetime
- 1996-10-07 DE DE69630969T patent/DE69630969T2/de not_active Expired - Fee Related
- 1996-10-07 HU HU9802348A patent/HUP9802348A3/hu unknown
- 1996-10-07 NZ NZ319948A patent/NZ319948A/en unknown
- 1996-10-07 CZ CZ981060A patent/CZ106098A3/cs unknown
- 1996-10-07 KR KR1019980702580A patent/KR19990064099A/ko not_active Ceased
- 1996-10-07 EA EA199800366A patent/EA001003B1/ru not_active IP Right Cessation
- 1996-10-07 AR ARP960104628A patent/AR003812A1/es not_active Application Discontinuation
- 1996-10-08 CO CO96053493A patent/CO4750819A1/es unknown
-
1998
- 1998-04-07 NO NO981578A patent/NO981578L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE255414T1 (de) | 2003-12-15 |
| JPH11513665A (ja) | 1999-11-24 |
| PL326294A1 (en) | 1998-09-14 |
| CO4750819A1 (es) | 1999-03-31 |
| NZ319948A (en) | 2000-06-23 |
| CZ106098A3 (cs) | 1999-03-17 |
| KR19990064099A (ko) | 1999-07-26 |
| WO1997013511A1 (en) | 1997-04-17 |
| AR003812A1 (es) | 1998-09-09 |
| DE69630969T2 (de) | 2004-10-21 |
| NO981578D0 (no) | 1998-04-07 |
| EP0854715A1 (en) | 1998-07-29 |
| EA001003B1 (ru) | 2000-08-28 |
| EP0854715A4 (en) | 2001-12-19 |
| HUP9802348A3 (en) | 1999-11-29 |
| ES2211981T3 (es) | 2004-07-16 |
| EA199800366A1 (ru) | 1998-10-29 |
| AU7259696A (en) | 1997-04-30 |
| US5731328A (en) | 1998-03-24 |
| HUP9802348A2 (hu) | 1999-08-30 |
| ZA968444B (en) | 1998-04-07 |
| AU716655B2 (en) | 2000-03-02 |
| EP0854715B1 (en) | 2003-12-03 |
| CN1199337A (zh) | 1998-11-18 |
| DE69630969D1 (de) | 2004-01-15 |
| CA2234404A1 (en) | 1997-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO973635L (no) | Fremgangsmåte for hemming av celle-celle adhesjon | |
| NO971520L (no) | Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y | |
| DK0652005T3 (da) | Fremgangsmåder til inhibering af endometriose | |
| NO944927L (no) | Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom | |
| MX9701360A (es) | Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. | |
| DK0659416T3 (da) | Inhibering af seborE og acne | |
| UA32427C2 (uk) | Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань | |
| NO944930D0 (no) | Hemming av dysfunksjonell uterin blödning | |
| NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
| NO944926L (no) | Fremgangsmåter for å inhibere myeloperoksidaseaktivitet | |
| NO944924L (no) | Fremgangsmåter for inhibering av Turner's syndrom | |
| NO975580L (no) | Fremgangsmåte for å inhibere melanom | |
| NO981578L (no) | FremgangsmÕte for hemming av plasminogenaktivatorhemmer I | |
| NO970786L (no) | Fremgangsmåte for hemming av benprotesedegradering | |
| NO973367L (no) | Fremgangsmåte for å inhibere miljömessige östrogen | |
| NO973609L (no) | Fremgangsmåte for å inhibere effektene av IL-6 | |
| NO971794L (no) | Fremgangsmåte for hemming av tilstander forbundet med bradykinin | |
| NO971029L (no) | Fremgangsmåter for hemming av endometriale metoser | |
| NO973103L (no) | Fremgangsmåte for inhibering av veksthormoneffekter | |
| NO970783L (no) | Fremgangsmåte for å hindre endometrialkreft | |
| NO20000750L (no) | FremgangsmÕte for Õ redusere blodplatetall | |
| NO944909L (no) | Fremgangsmåter for inhibering av mannlig infertilitet | |
| NO970785L (no) | Fremgangsmåte for benheling og fraktur-reparasjon | |
| NO983452L (no) | FremgangsmÕter for Õ hemme muskuloaponeurotisk fibromatose (desmoide tumorer) | |
| NO944910L (no) | Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |